Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Autologous Dendritic Cell Vaccine in Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Jodi Maranchie
- Target Recruit Count
- 42
- Registration Number
- NCT05127824
- Locations
- 🇺🇸
UPMC Department of Urology, Pittsburgh, Pennsylvania, United States
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 263
- Registration Number
- NCT05100082
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Cabozantinib and Pembrolizumab in Metastatic Pancreas
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Joseph Kim
- Target Recruit Count
- 21
- Registration Number
- NCT05052723
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 49
- Registration Number
- NCT05048901
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospita, Tainan, Taiwan
🇨🇳Changhua Christian Hospital, Changhua, Taiwan
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05048212
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05039736
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05039281
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05038839
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05019703
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lenvatinib with Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT05012371
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.